title: Localized skin necrosis by bevacizumab.
authors.forename: Laura
authors.initials: L
authors.lastname: Frances
authors.forename: Jaime
authors.initials: J
authors.lastname: Guijarro
authors.forename: Maria
authors.initials: M
authors.lastname: del Carmen Leiva-Salinas
authors.forename: Maria Pilar
authors.initials: MP
authors.lastname: Albares
authors.forename: Regina
authors.initials: R
authors.lastname: Ramon
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003875:Drug Eruptions / Q000473:pathology*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced; D012867:Skin / Q000473:pathology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin